SaaS Metrics
Academic Publication Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
AI Semantic Synergy Context
Connecting this academic literature to real-world market discussions and products.
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
AbstractThe glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell ty...
Semaglutide may lower risk of serious complications in high-risk diabetes
A new study suggests GLP-1 medications, such as semaglutide, were associated with better overall outcomes in people with type 2 diabetes and peripheral artery disease (PAD), particularly those at h...
The Best GLP-1 Drug on the Market Is Even Better Than We Knew
A pair of new studies suggest tirzepatide can keep heart disease at bay in high-risk groups.
Ozempic-like drugs may improve kidney disease outcomes: study
Research shows semaglutide — commonly sold as Ozempic or Wegovy — can improve kidney function and survival rates for people with some chronic diseases, even if they have heart issues.
Zepbound’s and Ozempic’s greatest benefit may be their anti-inflammatory power
A growing body of research suggests that GLP-1 drugs do more than control appetite and blood sugar. They could also fight inflammation
Frequently Asked Questions (FAQ)
Curated market intelligence mapped to this research.
What is the core focus of the research titled 'Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials'?
This literature focuses on:
Are there open-source GitHub repositories related to Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials?
Yes, open-source projects like DavidHDev/canvas-ui (A library of creative canvas components. Real HTML with WebGL effects running over it. React, Vue, Svelte, vanilla.) are actively building upon these concepts.
Which startups are commercializing the technology behind Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials?
Products like Vela are bringing this to market. Their focus is: Generate motion graphics with text. No After Effects.
What other academic literature is closely related to 'Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials'?
Yes, highly correlated activity was mapped. An entry titled 'Glucagon-like peptide-1 receptor: mechanisms and advances in therapy' discusses this: AbstractThe glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is ...
Are there commercial applications of 'Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials' in market news publications?
Yes, highly correlated activity was mapped. An entry titled 'Semaglutide may lower risk of serious complications in high-risk diabetes' discusses this: A new study suggests GLP-1 medications, such as semaglutide, were associated with better overall outcomes in people with type 2 diabetes and periph...
Cite this Market Intelligence Report
Reference our AI-mapped synergy between this research and the commercial market to instantly build authority.
Commercial Realization
Startups and Open Source tools heavily associated with the concepts explored in this paper.
-
GitHubDavidHDev/canvas-ui
-
GitHubshader-effects-inc/shaders
-
Product HuntVela
-
Product HuntZoomix